“GLP-1s give you gallstones.”
What the evidence shows
This one has solid evidence behind it. A 2022 meta-analysis of 76 randomized trials (103,371 participants, JAMA Internal Medicine) found GLP-1 drugs raised the risk of gallbladder and biliary disease — gallstones, cholecystitis — with a relative risk of about 1.37. The risk was notably higher when the drugs were used for weight loss (relative risk around 2.29) and at higher doses and longer durations. Two mechanisms explain it, and both are largely about the weight loss: rapid weight loss itself makes bile more likely to form stones, and GLP-1 drugs slow gallbladder emptying. In absolute terms the extra risk is modest — on the order of a couple dozen extra cases per 10,000 people per year in that analysis.
What we still don’t know
How much is the drug's direct effect on the gallbladder versus the rapid weight loss it drives isn't fully teased apart (fast weight loss by any method — including surgery and crash diets — raises gallstone risk). Whether slower titration or slower weight loss meaningfully lowers the risk is plausible but not firmly quantified.
Why the claim misleads
"Give you gallstones" is directionally correct but easily overblown. It's a real, measurable, mostly weight-loss-driven risk — not a unique poison and not common in absolute terms. The useful framing is awareness: new right-upper-abdominal pain (especially after fatty meals), with nausea or fever, is worth a prompt call to a clinician — rather than either dismissing the risk or treating it as a reason the drug is dangerous.
Graded by The Peptide Era · evidence, not hype